Eastern Bank’s Arbutus Biopharma ABUS Stock Holding History

Eastern Bank’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24K	Hold	5,000	–	–	﹤0.01%	739
2026 Q1	$22.5K	Hold	5,000	–	–	﹤0.01%	698
2025 Q4	$24.1K	Hold	5,000	–	–	﹤0.01%	695
2025 Q3	$22.7K	Hold	5,000	–	–	﹤0.01%	700
2025 Q2	$15.4K	Hold	5,000	–	–	﹤0.01%	709
2025 Q1	$17.4K	Hold	5,000	–	–	﹤0.01%	712
2024 Q4	$16.4K	Hold	5,000	–	–	﹤0.01%	720
2024 Q3	$19.3K	Buy	+5,000	New	+$19.2K	﹤0.01%	687

Other funds holding ABUS

LWA

Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Eastern Bank's ABUS Position: Q2 2026 in Review

Eastern Bank held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 5,000 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #739.

Eastern Bank first reported a position in ABUS in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.1K in Q4 2025. 4 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Eastern Bank held 5,000 shares of Arbutus Biopharma worth $24K as of Q2 2026.
Eastern Bank left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Eastern Bank's portfolio in Q2 2026, its #739 holding.
Eastern Bank first reported a position in Arbutus Biopharma in Q3 2024 and has held it in 8 quarters since.
Eastern Bank's Arbutus Biopharma position peaked at $24.1K in Q4 2025.
4 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.